AstraZeneca has reported positive full results from the phase III TULIP-SC trial, showing that subcutaneous (SC) Saphnelo (anifrolumab) significantly reduces disease activity in patients with systemic lupus erythematosus (SLE).
The full analysis was published in Arthritis & Rheumatology and confirms earlier interim findings.
Key Efficacy Results at Week 52
Subcutaneous Saphnelo met its primary endpoint.
BICLA response at Week 52:
- 56.2% with Saphnelo
- 37.1% with placebo
- Absolute difference: 19.1%
- p-value: 0.0002
These results align with prior intravenous (IV) Saphnelo trials.
Why This Matters for Lupus Care?
SLE remains a high-burden disease.
- Patients face early mortality risk
- Around 50% develop irreversible organ damage within five years
- Long-term oral corticosteroid (OCS) use is a key driver of damage
Reducing disease activity while tapering steroids is now a central treatment goal.
Alignment With New Treatment Guidelines
Recent lupus guidelines now prioritise:
- DORIS-defined remission
- Early biologic intervention
- OCS tapering toward discontinuation
The TULIP-SC data directly supports this shift.
Secondary and Exploratory Outcomes
Saphnelo showed consistent benefits across multiple endpoints.
Notable findings:
- 29.0% achieved DORIS remission
- 40.1% reached low disease activity (LLDAS)
- Faster BICLA responses
- Delayed time to first flare
- Effective disease control while tapering OCS to ≤7.5 mg/day
Safety and Tolerability
The safety profile of subcutaneous Saphnelo matched expectations.
- Overall adverse events were balanced versus placebo
- No new safety signals emerged
- Comparable to the known IV Saphnelo profile
Convenience Advantage: Subcutaneous Administration
Subcutaneous Saphnelo introduces a meaningful shift in care delivery.
What changes for patients:
- Once-weekly self-administration
- No mandatory infusion visits
- Option for home use or caregiver support
This expands access without compromising efficacy.
Regulatory Status
- IV Saphnelo: Approved in 70+ countries
- SC Saphnelo: Approved in the EU (December 2025)
- Under review: US, Japan, and other regions
More than 40,000 patients worldwide have been treated with Saphnelo to date.
About the TULIP-SC Trial
- Phase III, randomised, double-blind, placebo-controlled
- 367 patients with moderate-to-severe, autoantibody-positive SLE
- Weekly 120 mg SC anifrolumab vs placebo
- Standard therapy allowed in both arms
- 52-week primary period plus 52-week open-label extension
How Saphnelo Works?
Saphnelo is a first-in-class monoclonal antibody.
- Targets type I interferon receptor subunit 1
- Blocks IFN-alpha, IFN-beta, and IFN-kappa signalling
- Suppresses inflammatory pathways central to SLE
Type I interferon remains one of lupus’ most validated biological drivers.
Bigger Picture for AstraZeneca
Saphnelo anchors AstraZeneca’s Respiratory & Immunology strategy. The company is also evaluating anifrolumab in:
- Cutaneous lupus
- Lupus nephritis
- Myositis
- Systemic sclerosis
The ambition is clear: move lupus care toward sustained remission.
Bottom Line
The TULIP-SC trial confirms one thing clearly. Saphnelo’s efficacy translates seamlessly from IV to subcutaneous use.
For patients, this means:
- Proven disease control
- Fewer steroids
- Greater flexibility
- Less dependence on infusion centres
For lupus care, this is not incremental. It is structural progress.
